Patents
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
06/2002
06/20/2002WO2002047673A2 Methods and compositions to treat conditions associated with neovascularization
06/20/2002WO2002047669A1 Use of ep4 receptor agonists for treating neuropathic pain
06/20/2002WO2002047668A2 Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
06/20/2002WO2002047667A2 Novel medicament compositions based on anticholinesterase drugs and on a steroid
06/20/2002WO2002047663A1 Self emulsifying lipid matrix (selm)
06/20/2002WO2002047661A1 Pharmaceutical composition for intramuscular injection containing loxoprofen
06/20/2002WO2002047656A1 Compositions for retarding skin aging
06/20/2002WO2002030888A3 Tricyclic compounds and uses thereof
06/20/2002WO2002028905A3 Human anti-cd40 antibodies
06/20/2002WO2002024681A3 Pyrazine derivatives as modulators of tyrosine kinases
06/20/2002WO2002016436A3 ANTIBODIES TO HUMAN IL-1$g(b)
06/20/2002WO2002016312A3 NOVEL COMPOUNDS INHIBITING FACTOR Xa ACTIVITY
06/20/2002WO2002015943A3 Novel radiotherapeutic formulations containing 224ra and a method for their production
06/20/2002WO2002012243A3 SYNTHESIS OF (R)-3-(4-BROMOBENZYL)-1-(3,5-DICHLOROPHENYL)-5-IODO-3-METHYL-1-H-IMIDAZO[1,2-a]IMIDAZOL-2-ONE
06/20/2002WO2001087977A3 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
06/20/2002WO2001085959A3 Regulation of human lysostaphin-like protease
06/20/2002WO2001085942A3 Cytoskeleton-associated proteins
06/20/2002WO2001085096A3 Mast cell regulation
06/20/2002WO2001083524A3 Rna metabolism proteins
06/20/2002WO2001080825A3 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
06/20/2002WO2001077164A3 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis
06/20/2002WO2001076576A3 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
06/20/2002WO2001072830A3 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
06/20/2002WO2001044445A8 Human lyases and associated proteins
06/20/2002WO2001003688A3 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
06/20/2002WO2000067734A3 Use of phthalazine derivatives
06/20/2002WO2000061750A9 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS
06/20/2002WO2000061596A8 50 human secreted proteins
06/20/2002US20020077506 For therapy of inflammatory or painful disorder
06/20/2002US20020077465 Nuceotide sequences coding enzymatic polypeptide for use in the treatment and prevention of inflammation, cancer, muuscle disorders and thrombosis
06/20/2002US20020077460 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
06/20/2002US20020077361 Can be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects
06/20/2002US20020077360 Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition
06/20/2002US20020077356 Nonsteroidal antiinflammatory agents
06/20/2002US20020077353 Reacting 1-(3-Dimethylamino-1-propyl)-1-(4-fluorophenyl)-5-((trifluoromethyl)sulfonyl-oxy)-1,3-dihydroisobenzofurane or 1-(4'-fluorophenyl)-1- (3-dimethylaminopropyl)-5-bromophtalane with with a cyanide source in presence of palladium catalyst
06/20/2002US20020077351 For therapy and prophylaxis of diseases such as cachexia attributed to cancer or infections, rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus, rejection during bone marrow transplantation
06/20/2002US20020077346 For therapy of inflammatory and pain of a traumatic or pathologic origin
06/20/2002US20020077343 H2 receptor antagonist compounds in combination with nitric oxide donors, compostions and methods of use
06/20/2002US20020077342 For use in therapy of epilepsy, depression, tension, gastrointestinal disorders, pain, inflammation
06/20/2002US20020077340 Pyridone inhibitors of fatty acid binding protein and method
06/20/2002US20020077337 Chemical compounds
06/20/2002US20020077333 For therapy inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by tumor necrosis factor-alpha (TNF-alpha) and/or interleukin 6 or 10 and/or enzyme cyclooxygenase-2 (COX-2)
06/20/2002US20020077329 EP4 receptor inhibitors to treat rheumatoid arthritis
06/20/2002US20020077328 Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
06/20/2002US20020077316 For therapy and prophylaxis of cardiovascular disease, dyslipidemia; dyslipoproteinemia; disorder of glucose metabolism; Alzheimer's Disease; Syndrome X; peroxisome proliferator activated receptor-associated disorder
06/20/2002US20020077304 Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
06/20/2002US20020077293 Methods and compositions for the treatment of inflammatory diseases
06/20/2002US20020077283 Blocking interaction of caveolin with a protein in vivo by administering peptide which comprises caveolin scaffolding domain
06/20/2002US20020076793 Interleukin-1 beta converting enzyme like apoptosis protease-3 and 4
06/20/2002US20020076783 Plants and plants cells expressing histidine tagged intimin
06/20/2002US20020076705 Nucleotide sequences which code preferential polypeptide; for use in the detection, treatment, and prevention of alzheimer's, parkinson's, huntington's, Tourette Syndrome, meningitis, encephalitis, congenital disorders and brain
06/20/2002US20020076702 Evaluating prostaglandin response to preferential modulators; obtain sample, incubate with modulator, compare profile with control, determine if human had prostaglandin response to moduator based on differences in control and sample profiles
06/20/2002US20020076399 Treatment of immune diseases
06/20/2002US20020076395 Modified adipose tissue and related implants and methods
06/20/2002DE10063173A1 Harnstoff- und Urethanderivate Urea and urethane
06/20/2002DE10063008A1 Carbonsäureamidderivate Carboxamide
06/20/2002DE10062712A1 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden New pharmaceutical compositions based on anticholinergics and corticosteroids
06/20/2002CA2431852A1 Herbal pharmaceutical compositions for treating immunological disorders
06/20/2002CA2431766A1 Carboxymide derivatives and their use in the treatment of thromboembolic diseases and tumours
06/20/2002CA2430992A1 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
06/20/2002CA2430972A1 Fibrin fragments for treating inflammation
06/20/2002CA2428216A1 Secreted proteins
06/20/2002CA2427271A1 Inflammatory markers for detection and prevention of diabetes mellitus
06/19/2002EP1215214A1 Novel polypeptide
06/19/2002EP1215203A1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient
06/19/2002EP1214940A1 Methods of enhancing the therapeutic activity of NSAIDs and compositions of zwitterionic phospholipids useful therein
06/19/2002EP1214443A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells
06/19/2002EP1214422A1 Phosphatases which activate map kinase pathways
06/19/2002EP1214400A2 Zymogen activation system
06/19/2002EP1214396A1 Recombinant microorganisms expressing an oligosaccharide receptor mimic
06/19/2002EP1214350A1 Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm)
06/19/2002EP1214347A2 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
06/19/2002EP1214342A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies
06/19/2002EP1214337A2 Proteins associated with cell differentiation
06/19/2002EP1214318A1 Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives
06/19/2002EP1214305A1 Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation
06/19/2002EP1214304A1 Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
06/19/2002EP1214303A1 Heterocyclic compounds and methods of use thereof
06/19/2002EP1214292A1 Tyrosine derivatives
06/19/2002EP1214090A2 Novel uses of mammalian ccr6 receptors and related reagents
06/19/2002EP1214089A1 Therapeutic uses of m3 polypeptide
06/19/2002EP1214087A1 Combination treatment with il-1ra and compounds that inhibit il-1 processing and release
06/19/2002EP1214072A2 Use of desloratadine for treating allergic and inflammatory conditions
06/19/2002EP1214071A2 Treating allergic and inflammatory conditions using desloratadine
06/19/2002EP1214070A2 Polyhydroxylated benzene-containing compounds
06/19/2002EP1214064A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores
06/19/2002EP1105395B1 Photocyclized rapamycins
06/19/2002CN1354750A Amine derivatives compounds
06/19/2002CN1354672A Composition comprising alkaline sphingomyelinase for use as dietetic preparation, food supplement or pharmaceutical product
06/19/2002CN1354670A Therapeutic agent comprising botulinum neurotoxin
06/19/2002CN1354658A New use of compounds as antibacterial agents
06/19/2002CN1354655A Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents
06/19/2002CN1354653A Compressed compositions comprising clarified xanthan gum
06/19/2002CN1354652A Milling process for production of finely milled medicinal substances
06/19/2002CN1354640A Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
06/19/2002CN1354007A Medicated liquor for curing rheumatism and its production process
06/19/2002CN1353990A Preparation for analgesia and anesthesia or curing drug dependence
06/19/2002CN1086298C Ointment for rheumatic spur
06/18/2002US6407288 Naphthylsalicylanilides as antimicrobial and antiinflammatory agents
06/18/2002US6407250 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists